EBV status did not predict failure after nasopharyngeal cancer RT in Denmark
In 331 Danish NPC patients, five-year failure rates were similar by EBV status, while distant relapse was concentrated in locally advanced disease.
A free weekly digest of the radiation oncology research that matters.
Free forever. One email a week. Unsubscribe anytime.
In 331 Danish NPC patients, five-year failure rates were similar by EBV status, while distant relapse was concentrated in locally advanced disease.
Among 34 postoperative oral cavity cases, local failures occurred at or near the flap-native interface, with no recurrence inside the flap.
AYA patients face distinct radiation-related late effects and psychosocial challenges, yet age-specific dose constraints and prospective outcome data remain scarce.
Across 5,509 evaluable patients, 34% developed late chest-wall pain, although definitions and reported risk factors varied substantially.
Four quality-improvement measures reduced >3-mm chest-wall errors from 21.2% to 4.7%, but sternal marker placement increased skin reactions.
Interplay-related underdosage largely disappeared after five fractions, although two high-motion plans retained clinically relevant target deficits.
Distal targeting produced more overall pain relief, while proximal targeting yielded more complete pain freedom and medication discontinuation.
Bladder diameter >10 cm at simulation was associated with longer fractions, more interruptions and greater patient frustration during prostate RT.
Patients aged ≥70 reported similar or lower symptom burden, whereas PS ≥2 consistently predicted worse toxicity and slower recovery after radical RT.
Across 14 studies, 9 of 11 anxiety studies and 3 of 5 pain studies reported significant improvement with virtual reality.
In 223 previously irradiated patients, 3×10 Gy and 2×13 Gy salvage HDR brachytherapy produced similar disease control and late toxicity.
Across 52 studies, SGRT-assisted DIBH reduced mean heart dose by 1.21 Gy and LAD dose by 7.05 Gy versus free breathing.
After surgery plus 66–70 Gy, only one of six patients recurred locally, while half developed distant metastases.
Age ≥75 did not independently predict outcomes after proton therapy for HCC, while CCI ≥3 was associated with more than threefold higher mortality.
Across 26 studies, fatal toxicity clustered when BED10 >100 Gy was delivered to the whole tumor with concurrent platinum chemotherapy.